

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Martin Hermann Klemens BRUNE et al. : Attn: BOX PCT

Serial No. NEW : Docket No. 2001\_1463A

Filed September 25, 2001 :

ASSAYS FOR NUCLEOSIDE DIPHOSPHATES  
AND TRIPHOSPHATES

[Corresponding to PCT/GB00/01740

Filed May 5, 2000]

INFORMATION DISCLOSURE STATEMENTAssistant Commissioner for Patents,  
Washington, DC 20231

Sir:

Pursuant to the provisions of 37 CFR 1.56, 1.97 and 1.98, Applicants request consideration of [X] the references listed on attached form PTO-1449 and/or [] the additional information identified below in paragraph 3. A legible copy of each reference listed on the form PTO-1449 and each U.S. patent application listed below is enclosed, except a copy is not provided for each reference previously cited by or submitted to the Patent Office in international application no. PCT/GB00/01740.

1a. [X] This Information Disclosure Statement is submitted:

within three months of the filing date (or of entry into the National Stage) of the above-entitled application, or

before the mailing date of the first Office Action on the merits,

**and thus no certification and/or fee is required.**

1b.  This Information Disclosure Statement is submitted  
after the events of above paragraph 1a and prior to the mailing date of a final Office  
Action or a Notice of Allowance or an action which otherwise closes prosecution in the  
application, and thus:  
(1)  the certification of paragraph 2 below is provided, or  
(2)  the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.

1c.  This Information Disclosure Statement is submitted:  
after the mailing date of a final Office Action or Notice of Allowance or action which  
otherwise closes prosecution in the application, and prior to payment of the issue fee, and  
thus:  
**the certification of paragraph 2 below is provided, and**  
**the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.**

2. It is hereby certified

- a.  that each item of information contained in this Information Disclosure Statement  
was first cited in any communication from a foreign patent office in a counterpart  
foreign application not more than three months prior to the filing of the  
Statement, or
- b.  that no item of information contained in the Information Disclosure Statement  
was cited in a communication from a foreign patent office in a counterpart  
foreign application and, to the knowledge of the person signing the certification  
after making reasonable inquiry, was known to any individual designated in  
§1.56(c) more than three months prior to the filing of the Statement.

3.  Consideration of the following list of additional information (including any copending or  
abandoned U.S. application, prior uses and/or sales, etc.) is requested.

4. For each non-English language reference listed on the attached form PTO-1449, reference  
is made to:

- a.  a full or partial English language translation submitted herewith,
- b.  a foreign patent office search report (in the English language) submitted herewith,
- c.  the concise explanation contained in the specification of the present application at page,
- d.  the concise explanation set forth in the attached English language abstract,
- e.  the concise explanation set forth below or on a separate sheet attached to the reference:

5.  A foreign patent office search report citing one or more of the references is enclosed along with the Written Opinion, Applicant's comments on the Written Opinion, Notification Concerning Informal Communications with the Applicant, Letter dated June 19, 2001 from Carpmeals & Ransford and Notification of Transmittal of the International Preliminary Examination Report.

Respectfully submitted,

Martin Hermann Klemens BRUNE et al.

By Warren Cheek Jr.  
Warren M. Cheek, Jr.  
Registration No. 33,967  
Attorney for Applicants

WMC/dlk  
Washington, D.C. 20006-1021  
Telephone (202) 721-8200  
Facsimile (202) 721-8250  
September 25, 2001